10.19.11
Quintiles has acquired VCG & Associates and VCG BIO, based in Holliston, MA, and Cave Creek, AZ, respectively. VCG adds to Quintiles’ commercial services in sales and brand solutions, product solutions, product distribution and market access. VCG develops strategic healthcare marketing initiatives to address the challenges with U.S. pharmaceutical market entry, and focuses on biopharma companies that need supplemental resources to maximize commercial opportunities. VCG has experience in the areas of market access, distribution and reimbursement implementation.
“VCG complements our solutions and capabilities within both our Commercial and Consulting divisions with emerging biopharma, companies looking to establish a commercial presence in the U.S., and drug development companies entering the commercial space for the first time,” said Rich Pilnik, president, Global Commercial Solutions. “By creating virtual companies — utilizing market access services, proven distribution channels and reimbursement strategies — biopharma can bring needed therapies to market faster and more efficiently.”
“Our team is very excited to join Quintiles,” saidVCG co-founder and managing partner Brad Fleahman. “We have worked closely with Quintiles for the past several years, and this acquisition is a natural step that allows both organizations to serve our customers with specialized commercialization offerings. VCG will continue to provide our customers the same high level of service from our talented employees and trusted business operations and processes, while drawing upon Quintiles’ complementary expertise and services.”
“VCG complements our solutions and capabilities within both our Commercial and Consulting divisions with emerging biopharma, companies looking to establish a commercial presence in the U.S., and drug development companies entering the commercial space for the first time,” said Rich Pilnik, president, Global Commercial Solutions. “By creating virtual companies — utilizing market access services, proven distribution channels and reimbursement strategies — biopharma can bring needed therapies to market faster and more efficiently.”
“Our team is very excited to join Quintiles,” saidVCG co-founder and managing partner Brad Fleahman. “We have worked closely with Quintiles for the past several years, and this acquisition is a natural step that allows both organizations to serve our customers with specialized commercialization offerings. VCG will continue to provide our customers the same high level of service from our talented employees and trusted business operations and processes, while drawing upon Quintiles’ complementary expertise and services.”